Skip to main content

Home/ Dr. Goodyear/ Group items matching "Advanced" in title, tags, annotations or url

Group items matching
in title, tags, annotations or url

Sort By: Relevance | Date Filter: All | Bookmarks | Topics Simple Middle
13More

Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignan... - 0 views

www.ncbi.nlm.nih.gov/...PMC3665464 TK-1 TK-1 cancer thymidine kinase 1 cancer biomarker
shared by Nathan Goodyear on 04 Mar 15 - No Cached
  • Thymidine kinase 1 (TK1) is a proliferation biomarker
  • Nuclear TK1 expression in early grade CIN predicts risk for progression to malignancy
  • Nuclear TK1 expression is also a prognostic factor for treatment outcome
  • ...9 more annotations...
  • TK1 LI was found to be a more reliable prognostic marker for 5-year survival than pathological stages, FIGO stages and Ki-67,
  • nuclear TK1 expression is a reliable prognostic factor in CIN patients, a group of cervical lesion patients that respond positively to treatment
  • nuclear TK1 expression is correlated with advanced stage of invasive cervical carcinomas
  • a low TK1 LI can help to identify with a better survival
  • low TK1 expression in the tumors in these patients might indicate that these tumors have a lower proliferation rate
  • TK1 is a key kinase in the one-step salvage pathway by which thymidine is introduced into DNA via the salvage pathway
  • TK1 participates in DNA synthesis and is therefore closely related to the S-phase of the cell cycle, and is correlated with proliferation
  • TK1 intensity (TK1 synthesis rate) increases from CIN grade I to CIN grade III, but does not further increase in invasive cervical carcinomas.
  • TK1 intensity seems to be a prognostic factor particularly when pre-malignant cervical lesions progress to malignancy
  • Nathan Goodyear on 04 Mar 15
     
    TK-1 is a proliferation biomarker of DNA repair. TK-1 is a nuclear biomarker of cancer prognosis, survival, recurrence and predicts risk of progression of pre-malignant disease.
1More

Testosterone in Men with Advanced Li... [J Gastroenterol Hepatol. 2014] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...25087838 Testosterone men male hormone hormones cirrhosis liver disease
shared by Nathan Goodyear on 05 Aug 14 - No Cached
  • Nathan Goodyear on 05 Aug 14
     
    published ahead of print.  The authors conclude that the Testosterone therapy in hypogonadal men with cirrhosis requires further study.  They, the authors, state that the risk of Testosterone and hepatocellular carcinoma is overstated.  This risk is associated with oral Testosterone replacement and thus in that light is not overstated.  The majority of treatment strategies today employ none oral routes of administration which would support their statement.
20More

Differential Effects of Dehydroepiandrosterone and Testosterone in Prostate and Colon C... - 0 views

press.endocrine.org/...en.2012-2249 testosterone prostate colon colon cancer cancer NGF nerve growth factor dhea dehydroepiandrosterone
shared by Nathan Goodyear on 19 Nov 14 - No Cached
  • Several studies indicate that DHEA may enhance cancer-promoting activities in several prostate cancer cell lines acting as agonist or antagonist for the intracellular AR
  • the estrogenic metabolites of DHEA, 5a-androstane-3b, 17b-diol (3b-Adiol) and E2 bind to estrogen receptors but not to AR
  • no specific receptor has been identified for DHEA
  • ...16 more annotations...
  • Different members of neurotrophins are expressed during cancer progression, suggesting their involvement in cell proliferation, anoikis protection, and malignancy
  • Regulation of the apoptotic machinery in prostate and colon cancer cells by testosterone occurs rapidly and is initiated at the plasma membrane level through specific membrane-binding sites not involving the classical cytoplasmic AR
  • testosterone exerts potent regulatory effects on prostate and colon cancer cell apoptosis
  • Testosterone increased cell death in a dose-dependent manner
  • testosterone antagonizes the prosurvival effects of DHEA in neuronal cells, blocking its binding to NGF receptors
  • treatment of cells with DHEA exerted a strong antiapoptotic effect,
  • Androgens hold a central role in prostate and colon cancer biology
  • elevated levels of DHEA or its sulfate ester DHEA-sulfate in young adults are associated to low incidence of androgen-dependent tumors
  • DHEA may play a protective role in young prostate
  • The decline of DHEA with aging may contribute to prostate cancer progression associated with advanced age
  • DHEA is an effective antiapoptotic factor, reversing the serum deprivation-induced apoptosis in prostate cancer cells (DU145 and LNCaP cell lines) as well as in colon cancer cells
  • NGF appears to exert similar antiapoptotic actions in both prostate and color cancer cells
  • exposure of prostate DU145 and colon Caco2 cancer cells to testosterone totally blocked the protective effects of both DHEA and NGF. These findings suggest that testosterone acts as an antagonist of DHEA and NGF
  • These findings support the hypothesis that testosterone may inhibit cancer cell growth by antagonizing the proliferative, antiapoptotic effects of endogenous factors, such as DHEA or NGF, in the case of prostate and colon cancer cells
  • intratumor hormonal microenvironment may play a critical role in tumor progression.
  • The paracrine interactions of androgens with locally produced NGF may define tumor cell fate
  • Nathan Goodyear on 19 Nov 14
     
    Full article of previously posted abstract.  Cancers are unique.  Not all cancers are alike.  Whether they are tissue specific or not, cancers are unique.  This article describes the uniqueness of DHEA and Testosterone cancer, with particular attention to colon.
17More

Testosterone for the aging male; current evidence and recommended practice - 0 views

www.ncbi.nlm.nih.gov/...PMC2544367 leptin Testosterone low T low Testosterone male hormone hormones
shared by Nathan Goodyear on 27 Oct 14 - No Cached
  • Total serum testosterone consists of free testosterone (2%–3%), testosterone bound to sex hormone binding globulin (SHBG) (45%) and testosterone bound to other proteins (mainly albumin −50%)
  • Testosterone binds only loosely to albumin and so this testosterone as well as free testosterone is available to tissues and is termed bioavailable testosterone
  • Testosterone bound to SHBG is tightly bound and is biologically inactive
  • ...13 more annotations...
  • Bioavailable and free testosterone are known to correlate better than total testosterone with clinical sequelae of androgenization such as bone mineral density and muscle strength
  • peak levels seen in the morning following sleep, which can be maintained into the seventh decade
  • Samples should always be taken in the morning before 11 am
  • The reliable measurement of serum free testosterone requires equilibrium dialysis. This is not appropriate for clinical use as it is very time consuming and therefore expensive.
  • With increasing age, a greater number of men have total testosterone levels just below the normal range or in the low-normal range. In these patients total testosterone can be an unreliable indicator of hypogonadal status.
  • It is advised that at least two serum testosterone measurements, taken before 11 am on different mornings, are necessary to confirm the diagnosis.
  • Patients with serum total testosterone consistently below 8 nmol/l invariably demonstrate the clinical syndrome of hypogonadism and are likely to benefit from treatment. Patients with serum total testosterone in the range 8–12 nmol/l often have symptoms attributable to hypogonadism and it may be decided to offer either a clinical trial of testosterone treatment or to make further efforts to define serum bioavailable or free testosterone and then reconsider treatment. Patients with serum total testosterone persistently above 12 nmol/l do not have hypogonadism and symptoms are likely to be due to other disease states or ageing per se so testosterone treatment is not indicated.
  • Total testosterone levels fall at an average of 1.6% per year whilst free and bioavailable levels fall by 2%–3% per year.
  • With advancing age there is also a reduction in androgen receptor concentration in some target tissues and this may contribute to the clinical syndrome of LOH
  • Metabolic clearance declines with age
  • Gonadotrophin levels rise during aging (Feldman et al 2002) and testicular secretory responses to recombinant human chorionic gonadotrophin (hCG) are reduced
  • There are changes in the lutenising hormone (LH) production which consist of decreased LH pulse frequency and amplitude, (Veldhuis et al 1992; Pincus et al 1997) although pituitary production of LH in response to pharmacological stimulation with exogenous GnRH analogues is preserved
  • the decreases in testosterone levels with aging seem to reflect changes at all levels of the hypothalamic-pituitary-testicular axis
  • Nathan Goodyear on 27 Oct 14
     
    Leptin inhibits male Testosterone production at the level of the hypothalamus and at the testicle level.
1More

Karma KM 2500 Wheelchair - 0 views

www.wheelchairmanufacturers.in/...KM-2500-Small-Wheel-Wheelchair Lightweight Karma KM 2500 Small Wheelchair Overall Collapsed Width KM 2500 Wheelchair Karma KM 2500 Wheelchair Karma KM 2500 convenience and comfort to the user benefit of increased mobility
shared by wheelchairindia9 on 19 Oct 15 - No Cached
  • wheelchairindia9 on 19 Oct 15
     
    Karma KM 2500 Small Wheel Wheelchair: Karma KM 2500 Small Wheel Wheelchair Specifications: Width 18" Front/Rear Wheels 6" to 14" Seat Width 47cm Seat Depth 40cm Overall Width 66cm Overall Collapsed Width 36cm Armrest Height 21cm Overall Length 90cm Seat Height 47cm Backrest Height 38cm Overall Height 86cm Weight 9.2 k.g. Karma KM 2500 Small Wheel Wheelchair Seat and Back: AEGIS Microbe Shield Approved by the FDA, EPA, EU, etc., bonded anti-microbial barrier upholstery protects from odor, staining and deterioration from bacteria, fungus and other microorganisms. It is a shield for your health. Karma KM 2500 Small Wheel Wheelchair Extended Armrest: By simulating the natural position of arms, the extended armrest design is ergonomic and creates bigger seating space. An Ultra lightweight wheelchair (9.2 kg) with a compact design for either attendant assisted or self propelling users. The use of aircraft-grade aluminium alloy and double cross brace provide this model with outstanding strength and durability. Karma Healthcare KM-2500 Premium Wheelchair is amazingly light and compact transit wheelchair which is ideal for outings and travelers. It folds down to take up virtually no space in the boot of a car and weighs just over 9.2 kg making it easy for anyone to lift into a vehicle. Backrest folds-down for easy transportation. Maximum user weight: 100 K.g. Aluminium frame. Fixed armrest/fixed footrest. Foldable frame via double cross bars. Comfortable & durable upholstery. Swing-away foot plates. Puncture proof tyres. Attendant cable brake. 14" flat-free rear wheels. Detachable and washable cushion. One Year Warranty. It folds down to take up virtually no space in the boot of a car. This amazingly light and compact transit wheelchair is ideal for outings and travelling. It comes with detachable and washable cushion. The wheel chair has attendant cable brake. It is made from aircraft-grade aluminium alloy fra
1More

Advances in treatment of ulcerative colitis with herbs: From bench to bedside - 0 views

www.ncbi.nlm.nih.gov/...PMC4202341 curcumin natural therapies wheat grass butyrate aloe vera aloe ulcerative colitis UC IBD inflammatory bowel disease herbs
shared by Nathan Goodyear on 25 Jan 16 - No Cached
  • Nathan Goodyear on 25 Jan 16
     
    additional reviews of natural therapies and IBD.
1More

Challenging the Fructose Hypothesis: New Perspectives on Fructose Consumption and Metab... - 0 views

advances.nutrition.org/...246.full fructose nutrition metabolism HFCS high fructose corn syrup
shared by Nathan Goodyear on 18 Nov 15 - No Cached
  • Nathan Goodyear on 18 Nov 15
     
    good historical perspective of the data on fructose
1More

Efficacy of the concomitant administration of the pineal hormone melatonin in cancer im... - 0 views

www.ncbi.nlm.nih.gov/...8208518 IL-2 melatonin cancer immunotherapy
shared by Nathan Goodyear on 01 Jun 18 - No Cached
  • Nathan Goodyear on 01 Jun 18
     
    melatonin found to enhance the IL-2 anti-tumor activity in preliminary study.
1More

[Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small... - 0 views

www.ncbi.nlm.nih.gov/...18241646 Artesunate cancer NSCLC "non-small cell lung cancer"
shared by Nathan Goodyear on 11 Dec 18 - No Cached
  • Nathan Goodyear on 11 Dec 18
     
    Artesunate augments cisplatin and navelbine.
22More

Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer t... - 0 views

www.sciencedirect.com/...S0960977617300103 HER-2 breast cancer cancer herceptin Perjeta
shared by Nathan Goodyear on 06 Aug 18 - No Cached
  • 15%–20%
  • key mediator of cell growth, differentiation, and survival
  • of higher histological grade and are more likely to invade axillary lymph nodes
  • ...15 more annotations...
  • shortened survival and an increased risk of disease recurrence and metastasis
  • Currently, four HER2-directed agents are approved for the treatment of patients with HER2+ breast cancer: trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1)
  • biosimilars
  • trastuzumab may provide greater benefit when administered concurrently with chemotherapy rather than after, and this has become the standard approach
  • concurrent use of anthracyclines (ie, doxorubicin or epirubicin) and trastuzumab is not recommended because of an increased risk for cardiac toxicity
    • Nathan Goodyear
      Nathan Goodyear on 06 Aug 18
       
      avoid herceptin in conjuction with antracyclines i.e. doxorubicin
  • Sequential doxorubicin plus cyclophosphamide followed by concomitant paclitaxel or docetaxel and trastuzumab is recommended for most patients
    • Nathan Goodyear
      Nathan Goodyear on 06 Aug 18
       
      top recommended regimen combination
  • Guidelines also recommend trastuzumab in combination with paclitaxel, docetaxel and carboplatin, or docetaxel and cyclophosphamide, particularly for patients with increased risk for cardiac toxicity or those with small (≤1 cm), node-negative HER2+ tumors
    • Nathan Goodyear
      Nathan Goodyear on 06 Aug 18
       
      good alternative in patients with increased risk of cardiac toxicity.
  • guidelines recommend up to 1 year of adjuvant trastuzumab
  • Neoadjuvant chemotherapy with trastuzumab is associated with higher rates of pathologic complete response (pCR) than chemotherapy alone or in combination with lapatinib
  • the combination of trastuzumab, lapatinib, and chemotherapy is not recommended because it failed to demonstrate noninferiority versus trastuzumab and chemotherapy in the adjuvant setting
  • recommend the combination of trastuzumab, pertuzumab, and chemotherapy as neoadjuvant treatment for patients with locally advanced HER2+ breast cancer and for some patients (node-positive or tumor ≥2 cm) with early-stage disease
  • neoadjuvant chemotherapy in combination with pertuzumab and trastuzumab reduced the risk of progression or death by 31% and recurrence or death by 40% versus trastuzumab alone
  • Concurrent chemotherapy and HER2-directed therapy improves survival outcomes over chemotherapy alon
  • dual inhibition of HER2 with trastuzumab and pertuzumab in combination with paclitaxel reduced the risk of death or progression by approximately 40% compared with concurrent trastuzumab and paclitaxel
  • the combination of trastuzumab, pertuzumab, and taxane chemotherapy is the preferred first-line regimen
  • Nathan Goodyear on 06 Aug 18
     
    HER-2 + breast cancer = appx 15-20% of all breast cancers and is a marker of worse prognosis and an indication for targeted immunotherapy blockade.
20More

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multi... - 0 views

www.ncbi.nlm.nih.gov/...PMC5809128 cancer anal cancer nivolumab immunotherapy
shared by Nathan Goodyear on 13 Jul 18 - No Cached
  • Patients received a median of six doses of nivolumab
  • four of the first 12 patients had partial responses
  • Nine (24% [95% CI 15–33]) of 37 patients achieved a response (seven partial responses and two complete responses
  • ...16 more annotations...
  • no treatment-related deaths
  • the most common adverse events were anaemia (26 [70%]), fatigue (25 [68%]), and rash
  • hypothyroidism
  • hypothyroidism
  • nivolumab-related autoimmune hypothyroidism, which resolved after a short course of corticosteroids
  • No grade 3 or 4 adverse events occurred
  • Nivolumab resulted in objective responses in 24% of patients with metastatic SCCA
  • Historically, doublet chemotherapy with cisplatin and fluorouracil has been the most common treatment for patients with metastatic SCCA
  • our results suggest that immune checkpoint blockade agents might extend overall survival beyond currently available therapies, especially if provided early in the disease treatment course
  • the dose of nivolumab we used differs from the 2016 recommendation of a fixed 240 mg every 2 weeks
  • 25% of patients develop distant metastases
  • most patients with localised SCCA are cured by chemoradiation
  • More than 90% of cases of SCCA are linked to prior infection with human papillomavirus (HPV)
  • Within tumour cells, HPV oncoproteins are immunogenic and can trigger an anti-tumour host immune response by recruitment of tumour-infiltrating lymphocytes
  • Tumour cells express PD-L1 and, on binding its inhibitory receptor PD-1 on the surface of T cells, downregulate T-cell activation and thwart the local anti-tumour immune response
  • Nivolumab is a humanised monoclonal antibody against PD-1 that disrupts this interaction, enabling T-cell cytotoxicity. It has activity as a monotherapy in advanced solid cancers, such as head and neck cancer, melanoma, non-small-cell lung cancer, and renal cell carcinoma
  • Nathan Goodyear on 13 Jul 18
     
    study finds nivolumab helpful in some patients with surgically unresectable or metastatic anal cancer.  The dose used was 3 mg/kg every 2 weeks. 
15More

Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor,... - 0 views

europepmc.org/...PMC2510818 GC-MAF Nagalase cancer prostate cancer immunotherapy PSA
shared by Nathan Goodyear on 08 May 18 - No Cached
  • the MAF precursor activity of prostate cancer patient Gc protein is lost or reduced, because their serum Gc protein is deglycosylated by serum α-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells
  • Administration of 100 ng of GcMAF
  • 100 ng of GcMAF was administered intramuscularly once a week
  • ...11 more annotations...
  • As GcMAF therapy progressed the MAF precursor activity of all five patients increased and their serum Nagalase activity decreased inversely
  • As GcMAF therapy progressed, the MAF precursor activity increased with a concomitant decrease in serum Nagalase activity
  • serum Nagalase is proportional to tumor burden
  • as GcMAF therapy progressed, serum Nagalase activity decreased and, concomitantly, tumor burden decreased
  • the serum Nagalase activities of all 16 patients decreased as GcMAF therapy progressed
  • annual computed tomographic scans of these patients confirmed them being tumor recurrence-free for the 7 years
  • undifferentiated cells were killed rapidly during the first few weeks, and the differentiated cells were killed slowly in the remaining GcMAF therapeutic period
  • PSA levels of prostatectomized patients decreased as serum Nagalase decreased during GcMAF therapy
  • In patients without tumor resection, however, although serum Nagalase activity decreased as GcMAF therapy progressed, their PSA values remained unchanged. The result suggests that the PSA derived from tumor-bearing prostate did not change while tumor burden decreased. Because tumor-induced inflammation in the noncancerous prostate tissues causes secretion of PSA [38], the PSA produced from these inflamed noncancerous prostate tissues cannot be changed by the decrease in tumor burden
  • Advanced cancer patients have high serum Nagalase activities, resulting in no macrophage activation and severe immunosuppression that explain why cancer patients die with overwhelming infection
  • Prognostic utility of serum α-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients
  • Nathan Goodyear on 08 May 18
     
    GC-MAF levels exist in inverse relationship to nagalase.  In this study of men with prostate cancer, weekly GCMAF injections reduced Nagalase activity to levels found in healthy controls suggesting tumor free. The dose was 100 ng/week. Nagalase is a protein that suppresses GC-MAF production and thus is immunosuppressive.
1More

Hypercalcemia: A Complication of Advanced Chronic Liver Disease | JAMA Internal Medicin... - 0 views

jamanetwork.com/...607804 liver hypercalcemia liver disease
shared by Nathan Goodyear on 21 Aug 18 - No Cached
  • Nathan Goodyear on 21 Aug 18
     
    Hypercalcemia is a common finding in liver disease, especially cancer of the liver, whether primary or mets.  Also, consider hyperparathyroidism and excessive vitamin D supplementation.
1More

Management of Bleeding in Patients with Advanced Cancer - 0 views

theoncologist.alphamedpress.org/...561.long cancer bleeding octreotide
shared by Nathan Goodyear on 24 Aug 18 - No Cached
  • Nathan Goodyear on 24 Aug 18
     
    therapies to try and control GI bleeding.
1More

Advanced Gastric Cancer Associated with Disseminated Intravascular Coagulation Successf... - 0 views

www.ncbi.nlm.nih.gov/...PMC3705133 DIC cancer
shared by Nathan Goodyear on 03 Jul 18 - No Cached
  • Nathan Goodyear on 03 Jul 18
     
    Case study of DIC in patient with gastric cancer successfully treated with 5-fu and oxaliplatin.
1More

Long‐acting octreotide versus placebo for treatment of advanced HCC: A random... - 0 views

aasldpubs.onlinelibrary.wiley.com/...hep.21468 octreotide GH growth hormone cancer liver cancer
shared by Nathan Goodyear on 09 Jul 18 - No Cached
  • Nathan Goodyear on 09 Jul 18
     
    Octreotide, GH inhibitor, no better than placebo in liver cancer.
1More

Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic ca... - 0 views

www.ncbi.nlm.nih.gov/...9307718 adenoid cystic carcinoma
shared by Nathan Goodyear on 03 Oct 18 - No Cached
  • Nathan Goodyear on 03 Oct 18
     
    adenoid cystic carcinoma abstract.
1More

Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colo... - 0 views

academic.oup.com/...5038128 insulin diet nutrition cancer colon cancer
shared by Nathan Goodyear on 26 Jun 18 - No Cached
  • Nathan Goodyear on 26 Jun 18
     
    New prospective study of 1023 patients finds that high-insulogenic diet, also know as a traditional American diet, high glycemic, high sugar diet... is associated with an increased risk of cancer recurrence and mortality compared to low insulogenic diet.  The authors concluded that this would be beneficial for after surgical resection in people with stage III colon cancer. My question, is why wait on the development of cancer: use a low-insulogenic diet to prevent the cancer all together or when diagnosed implement immediately.  Why wait? Treat early! Prevent!
1More

Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer ... - 0 views

www.ncbi.nlm.nih.gov/...PMC5992645 Tumor associate macrophages cancer ferritin
shared by Nathan Goodyear on 18 Apr 19 - No Cached
hoangkimchi liked it
  • Nathan Goodyear on 18 Apr 19
     
    Ferritin is increased as a byproduct of the inflammation, which studies suggest, are the result of TAMs. Some ferritin is also likely the result of release from cell death. L-ferritin is the most prevalent in cancer. Elevated ferritin is associated with a poor prognosis in many cancers. It also correlates with CRP, WBC in this study. 1 mg/ml of serum ferritin correlates to 8mg of stored Fe.
1More

Epigenetics: A New Bridge between Nutrition and Health - 0 views

advances.nutrition.org/...8.full nutrition epigenetics
shared by Nathan Goodyear on 09 Oct 17 - No Cached
  • Nathan Goodyear on 09 Oct 17
     
    7 year old study, though very much still relevant.  Nutrition effects epigenetics.
« First ‹ Previous 141 - 160 of 250 Next › Last »
Showing 20▼ items per page